ProCE Banner Activity

DACOTA Phase III Study of Decitabine vs Hydroxyurea for Advanced Proliferative CMML

Slideset Download
Conference Coverage
In this phase III study in patients with newly diagnosed advanced myeloproliferative CMML comparing decitabine vs hydroxyurea no differences in EFS, OS, or transformation to AML were reported.

Released: December 14, 2020

Expiration: December 13, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology